nodes	percent_of_prediction	percent_of_DWPC	metapath
Valganciclovir—Valaciclovir—SLC10A2—esophageal cancer	0.0275	0.522	CrCbGaD
Valganciclovir—Aciclovir—SLC10A2—esophageal cancer	0.0251	0.478	CrCbGaD
Valganciclovir—SLC6A14—digestive system—esophageal cancer	0.0196	0.33	CbGeAlD
Valganciclovir—SLC6A14—lung—esophageal cancer	0.0164	0.276	CbGeAlD
Valganciclovir—SLC15A1—epithelium—esophageal cancer	0.00651	0.109	CbGeAlD
Valganciclovir—SLC15A1—digestive system—esophageal cancer	0.00495	0.0833	CbGeAlD
Valganciclovir—SLC6A14—NRF2 pathway—ALDH3A1—esophageal cancer	0.00433	0.0715	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—esophageal cancer	0.00406	0.067	CbGpPWpGaD
Valganciclovir—SLC15A2—bronchus—esophageal cancer	0.00401	0.0674	CbGeAlD
Valganciclovir—SLC6A14—NRF2 pathway—BLVRB—esophageal cancer	0.00386	0.0637	CbGpPWpGaD
Valganciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—esophageal cancer	0.00371	0.0613	CbGpPWpGaD
Valganciclovir—SLC15A2—trachea—esophageal cancer	0.0036	0.0605	CbGeAlD
Valganciclovir—SLC6A14—NRF2 pathway—PRDX1—esophageal cancer	0.00328	0.0542	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—SLC39A6—esophageal cancer	0.00293	0.0483	CbGpPWpGaD
Valganciclovir—SLC6A14—NRF2 pathway—ADH7—esophageal cancer	0.00279	0.0461	CbGpPWpGaD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—esophageal cancer	0.00266	0.0439	CbGpPWpGaD
Valganciclovir—SLC15A2—lung—esophageal cancer	0.00259	0.0435	CbGeAlD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—ABCB1—esophageal cancer	0.00258	0.0425	CbGpPWpGaD
Valganciclovir—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.00257	0.00311	CcSEcCtD
Valganciclovir—Renal impairment—Capecitabine—esophageal cancer	0.00255	0.00308	CcSEcCtD
Valganciclovir—Renal failure—Cisplatin—esophageal cancer	0.00249	0.00302	CcSEcCtD
Valganciclovir—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00249	0.00301	CcSEcCtD
Valganciclovir—Stomatitis—Cisplatin—esophageal cancer	0.00247	0.00299	CcSEcCtD
Valganciclovir—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00243	0.00293	CcSEcCtD
Valganciclovir—Pain in extremity—Capecitabine—esophageal cancer	0.00243	0.00293	CcSEcCtD
Valganciclovir—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00241	0.00291	CcSEcCtD
Valganciclovir—Hepatobiliary disease—Cisplatin—esophageal cancer	0.0024	0.0029	CcSEcCtD
Valganciclovir—Migraine—Capecitabine—esophageal cancer	0.00239	0.00289	CcSEcCtD
Valganciclovir—Aplastic anaemia—Methotrexate—esophageal cancer	0.00234	0.00283	CcSEcCtD
Valganciclovir—Ataxia—Capecitabine—esophageal cancer	0.00228	0.00276	CcSEcCtD
Valganciclovir—Coma—Methotrexate—esophageal cancer	0.00227	0.00275	CcSEcCtD
Valganciclovir—Blood creatinine increased—Capecitabine—esophageal cancer	0.00227	0.00275	CcSEcCtD
Valganciclovir—Dehydration—Capecitabine—esophageal cancer	0.00226	0.00273	CcSEcCtD
Valganciclovir—Mouth ulceration—Methotrexate—esophageal cancer	0.00225	0.00272	CcSEcCtD
Valganciclovir—Neoplasm—Methotrexate—esophageal cancer	0.00225	0.00272	CcSEcCtD
Valganciclovir—Urinary tract disorder—Cisplatin—esophageal cancer	0.00225	0.00272	CcSEcCtD
Valganciclovir—Connective tissue disorder—Cisplatin—esophageal cancer	0.00224	0.00271	CcSEcCtD
Valganciclovir—Urethral disorder—Cisplatin—esophageal cancer	0.00223	0.0027	CcSEcCtD
Valganciclovir—Dry skin—Capecitabine—esophageal cancer	0.00222	0.00269	CcSEcCtD
Valganciclovir—Abdominal pain upper—Capecitabine—esophageal cancer	0.00222	0.00268	CcSEcCtD
Valganciclovir—Hypokalaemia—Capecitabine—esophageal cancer	0.00221	0.00267	CcSEcCtD
Valganciclovir—Visual impairment—Cisplatin—esophageal cancer	0.0022	0.00265	CcSEcCtD
Valganciclovir—Nasopharyngitis—Capecitabine—esophageal cancer	0.00217	0.00262	CcSEcCtD
Valganciclovir—Sepsis—Methotrexate—esophageal cancer	0.00216	0.00261	CcSEcCtD
Valganciclovir—Gastritis—Capecitabine—esophageal cancer	0.00215	0.0026	CcSEcCtD
Valganciclovir—Eye disorder—Cisplatin—esophageal cancer	0.00213	0.00257	CcSEcCtD
Valganciclovir—Tinnitus—Cisplatin—esophageal cancer	0.00212	0.00257	CcSEcCtD
Valganciclovir—Lymphadenopathy—Methotrexate—esophageal cancer	0.00212	0.00256	CcSEcCtD
Valganciclovir—Cardiac disorder—Cisplatin—esophageal cancer	0.00211	0.00256	CcSEcCtD
Valganciclovir—Abdominal distension—Capecitabine—esophageal cancer	0.00211	0.00255	CcSEcCtD
Valganciclovir—Influenza—Capecitabine—esophageal cancer	0.0021	0.00254	CcSEcCtD
Valganciclovir—Dysphagia—Capecitabine—esophageal cancer	0.0021	0.00254	CcSEcCtD
Valganciclovir—Thrombophlebitis—Methotrexate—esophageal cancer	0.00209	0.00252	CcSEcCtD
Valganciclovir—Diabetes mellitus—Methotrexate—esophageal cancer	0.00208	0.00251	CcSEcCtD
Valganciclovir—Immune system disorder—Cisplatin—esophageal cancer	0.00206	0.00249	CcSEcCtD
Valganciclovir—Mediastinal disorder—Cisplatin—esophageal cancer	0.00205	0.00248	CcSEcCtD
Valganciclovir—Sweating increased—Capecitabine—esophageal cancer	0.00204	0.00247	CcSEcCtD
Valganciclovir—Arrhythmia—Cisplatin—esophageal cancer	0.00204	0.00246	CcSEcCtD
Valganciclovir—SLC6A14—NRF2 pathway—ABCC2—esophageal cancer	0.00203	0.0335	CbGpPWpGaD
Valganciclovir—Bronchitis—Capecitabine—esophageal cancer	0.00202	0.00244	CcSEcCtD
Valganciclovir—Alopecia—Cisplatin—esophageal cancer	0.00201	0.00243	CcSEcCtD
Valganciclovir—Pancytopenia—Capecitabine—esophageal cancer	0.00199	0.00241	CcSEcCtD
Valganciclovir—Malnutrition—Cisplatin—esophageal cancer	0.00198	0.0024	CcSEcCtD
Valganciclovir—Dysuria—Capecitabine—esophageal cancer	0.00196	0.00237	CcSEcCtD
Valganciclovir—Neutropenia—Capecitabine—esophageal cancer	0.00196	0.00237	CcSEcCtD
Valganciclovir—Flatulence—Cisplatin—esophageal cancer	0.00195	0.00236	CcSEcCtD
Valganciclovir—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00195	0.00236	CcSEcCtD
Valganciclovir—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.00192	0.00231	CcSEcCtD
Valganciclovir—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00191	0.00231	CcSEcCtD
Valganciclovir—Muscle spasms—Cisplatin—esophageal cancer	0.00191	0.0023	CcSEcCtD
Valganciclovir—Weight decreased—Capecitabine—esophageal cancer	0.0019	0.00229	CcSEcCtD
Valganciclovir—Hyperglycaemia—Capecitabine—esophageal cancer	0.00189	0.00229	CcSEcCtD
Valganciclovir—SLC6A14—NRF2 pathway—NFE2L2—esophageal cancer	0.00189	0.0311	CbGpPWpGaD
Valganciclovir—Pneumonia—Capecitabine—esophageal cancer	0.00188	0.00227	CcSEcCtD
Valganciclovir—Infestation—Capecitabine—esophageal cancer	0.00187	0.00226	CcSEcCtD
Valganciclovir—Infestation NOS—Capecitabine—esophageal cancer	0.00187	0.00226	CcSEcCtD
Valganciclovir—Vision blurred—Cisplatin—esophageal cancer	0.00187	0.00226	CcSEcCtD
Valganciclovir—Depression—Capecitabine—esophageal cancer	0.00187	0.00225	CcSEcCtD
Valganciclovir—Tremor—Cisplatin—esophageal cancer	0.00186	0.00225	CcSEcCtD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.00184	0.0304	CbGpPWpGaD
Valganciclovir—Ill-defined disorder—Cisplatin—esophageal cancer	0.00184	0.00222	CcSEcCtD
Valganciclovir—Renal failure—Capecitabine—esophageal cancer	0.00184	0.00222	CcSEcCtD
Valganciclovir—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00183	0.00222	CcSEcCtD
Valganciclovir—Anaemia—Cisplatin—esophageal cancer	0.00183	0.00222	CcSEcCtD
Valganciclovir—Jaundice—Capecitabine—esophageal cancer	0.00182	0.0022	CcSEcCtD
Valganciclovir—Stomatitis—Capecitabine—esophageal cancer	0.00182	0.0022	CcSEcCtD
Valganciclovir—Urinary tract infection—Capecitabine—esophageal cancer	0.00182	0.0022	CcSEcCtD
Valganciclovir—Malaise—Cisplatin—esophageal cancer	0.00179	0.00216	CcSEcCtD
Valganciclovir—Haematuria—Capecitabine—esophageal cancer	0.00178	0.00216	CcSEcCtD
Valganciclovir—Leukopenia—Cisplatin—esophageal cancer	0.00178	0.00215	CcSEcCtD
Valganciclovir—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00177	0.00214	CcSEcCtD
Valganciclovir—SLC15A2—lymph node—esophageal cancer	0.00177	0.0297	CbGeAlD
Valganciclovir—Convulsion—Cisplatin—esophageal cancer	0.00172	0.00208	CcSEcCtD
Valganciclovir—Ataxia—Methotrexate—esophageal cancer	0.0017	0.00205	CcSEcCtD
Valganciclovir—Haemoglobin—Capecitabine—esophageal cancer	0.00169	0.00204	CcSEcCtD
Valganciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.00169	0.0278	CbGpPWpGaD
Valganciclovir—Anxiety—Cisplatin—esophageal cancer	0.00168	0.00203	CcSEcCtD
Valganciclovir—Haemorrhage—Capecitabine—esophageal cancer	0.00168	0.00203	CcSEcCtD
Valganciclovir—Hepatitis—Capecitabine—esophageal cancer	0.00168	0.00203	CcSEcCtD
Valganciclovir—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00168	0.00203	CcSEcCtD
Valganciclovir—Discomfort—Cisplatin—esophageal cancer	0.00167	0.00202	CcSEcCtD
Valganciclovir—Pharyngitis—Capecitabine—esophageal cancer	0.00167	0.00201	CcSEcCtD
Valganciclovir—Urinary tract disorder—Capecitabine—esophageal cancer	0.00166	0.002	CcSEcCtD
Valganciclovir—Oedema peripheral—Capecitabine—esophageal cancer	0.00165	0.002	CcSEcCtD
Valganciclovir—Connective tissue disorder—Capecitabine—esophageal cancer	0.00165	0.00199	CcSEcCtD
Valganciclovir—Urethral disorder—Capecitabine—esophageal cancer	0.00165	0.00199	CcSEcCtD
Valganciclovir—SLC6A14—NRF2 pathway—CYP2A6—esophageal cancer	0.00162	0.0268	CbGpPWpGaD
Valganciclovir—Oedema—Cisplatin—esophageal cancer	0.00162	0.00196	CcSEcCtD
Valganciclovir—Anaphylactic shock—Cisplatin—esophageal cancer	0.00162	0.00196	CcSEcCtD
Valganciclovir—Visual impairment—Capecitabine—esophageal cancer	0.00162	0.00196	CcSEcCtD
Valganciclovir—Infection—Cisplatin—esophageal cancer	0.00161	0.00194	CcSEcCtD
Valganciclovir—Nervous system disorder—Cisplatin—esophageal cancer	0.00159	0.00192	CcSEcCtD
Valganciclovir—Thrombocytopenia—Cisplatin—esophageal cancer	0.00158	0.00192	CcSEcCtD
Valganciclovir—Tachycardia—Cisplatin—esophageal cancer	0.00158	0.00191	CcSEcCtD
Valganciclovir—Skin disorder—Cisplatin—esophageal cancer	0.00157	0.0019	CcSEcCtD
Valganciclovir—Eye disorder—Capecitabine—esophageal cancer	0.00157	0.0019	CcSEcCtD
Valganciclovir—Tinnitus—Capecitabine—esophageal cancer	0.00157	0.00189	CcSEcCtD
Valganciclovir—Hyperhidrosis—Cisplatin—esophageal cancer	0.00156	0.00189	CcSEcCtD
Valganciclovir—Cardiac disorder—Capecitabine—esophageal cancer	0.00156	0.00188	CcSEcCtD
Valganciclovir—Eosinophilia—Methotrexate—esophageal cancer	0.00155	0.00187	CcSEcCtD
Valganciclovir—Anorexia—Cisplatin—esophageal cancer	0.00154	0.00186	CcSEcCtD
Valganciclovir—Pancreatitis—Methotrexate—esophageal cancer	0.00153	0.00185	CcSEcCtD
Valganciclovir—Angiopathy—Capecitabine—esophageal cancer	0.00152	0.00184	CcSEcCtD
Valganciclovir—Immune system disorder—Capecitabine—esophageal cancer	0.00152	0.00183	CcSEcCtD
Valganciclovir—Mediastinal disorder—Capecitabine—esophageal cancer	0.00151	0.00183	CcSEcCtD
Valganciclovir—Hypotension—Cisplatin—esophageal cancer	0.00151	0.00183	CcSEcCtD
Valganciclovir—Chills—Capecitabine—esophageal cancer	0.00151	0.00182	CcSEcCtD
Valganciclovir—Arrhythmia—Capecitabine—esophageal cancer	0.0015	0.00181	CcSEcCtD
Valganciclovir—Alopecia—Capecitabine—esophageal cancer	0.00148	0.00179	CcSEcCtD
Valganciclovir—Pancytopenia—Methotrexate—esophageal cancer	0.00148	0.00179	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00147	0.00178	CcSEcCtD
Valganciclovir—Mental disorder—Capecitabine—esophageal cancer	0.00147	0.00178	CcSEcCtD
Valganciclovir—Malnutrition—Capecitabine—esophageal cancer	0.00146	0.00177	CcSEcCtD
Valganciclovir—Dysuria—Methotrexate—esophageal cancer	0.00146	0.00177	CcSEcCtD
Valganciclovir—Neutropenia—Methotrexate—esophageal cancer	0.00146	0.00177	CcSEcCtD
Valganciclovir—Paraesthesia—Cisplatin—esophageal cancer	0.00145	0.00176	CcSEcCtD
Valganciclovir—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00145	0.00175	CcSEcCtD
Valganciclovir—Dyspnoea—Cisplatin—esophageal cancer	0.00144	0.00174	CcSEcCtD
Valganciclovir—Flatulence—Capecitabine—esophageal cancer	0.00144	0.00174	CcSEcCtD
Valganciclovir—Erectile dysfunction—Methotrexate—esophageal cancer	0.00144	0.00174	CcSEcCtD
Valganciclovir—Dysgeusia—Capecitabine—esophageal cancer	0.00143	0.00173	CcSEcCtD
Valganciclovir—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00143	0.00172	CcSEcCtD
Valganciclovir—Back pain—Capecitabine—esophageal cancer	0.00141	0.00171	CcSEcCtD
Valganciclovir—Decreased appetite—Cisplatin—esophageal cancer	0.00141	0.0017	CcSEcCtD
Valganciclovir—Muscle spasms—Capecitabine—esophageal cancer	0.00141	0.0017	CcSEcCtD
Valganciclovir—Pneumonia—Methotrexate—esophageal cancer	0.0014	0.00169	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.0014	0.00169	CcSEcCtD
Valganciclovir—Infestation NOS—Methotrexate—esophageal cancer	0.00139	0.00168	CcSEcCtD
Valganciclovir—Infestation—Methotrexate—esophageal cancer	0.00139	0.00168	CcSEcCtD
Valganciclovir—Depression—Methotrexate—esophageal cancer	0.00139	0.00168	CcSEcCtD
Valganciclovir—Pain—Cisplatin—esophageal cancer	0.00138	0.00167	CcSEcCtD
Valganciclovir—Vision blurred—Capecitabine—esophageal cancer	0.00138	0.00167	CcSEcCtD
Valganciclovir—Tremor—Capecitabine—esophageal cancer	0.00137	0.00166	CcSEcCtD
Valganciclovir—Renal failure—Methotrexate—esophageal cancer	0.00137	0.00165	CcSEcCtD
Valganciclovir—Stomatitis—Methotrexate—esophageal cancer	0.00136	0.00164	CcSEcCtD
Valganciclovir—Ill-defined disorder—Capecitabine—esophageal cancer	0.00136	0.00164	CcSEcCtD
Valganciclovir—Anaemia—Capecitabine—esophageal cancer	0.00135	0.00163	CcSEcCtD
Valganciclovir—Feeling abnormal—Cisplatin—esophageal cancer	0.00133	0.00161	CcSEcCtD
Valganciclovir—Haematuria—Methotrexate—esophageal cancer	0.00133	0.0016	CcSEcCtD
Valganciclovir—Malaise—Capecitabine—esophageal cancer	0.00132	0.00159	CcSEcCtD
Valganciclovir—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00132	0.00159	CcSEcCtD
Valganciclovir—Vertigo—Capecitabine—esophageal cancer	0.00131	0.00159	CcSEcCtD
Valganciclovir—Leukopenia—Capecitabine—esophageal cancer	0.00131	0.00158	CcSEcCtD
Valganciclovir—Body temperature increased—Cisplatin—esophageal cancer	0.00128	0.00155	CcSEcCtD
Valganciclovir—Cough—Capecitabine—esophageal cancer	0.00128	0.00154	CcSEcCtD
Valganciclovir—Hypertension—Capecitabine—esophageal cancer	0.00126	0.00153	CcSEcCtD
Valganciclovir—Haemoglobin—Methotrexate—esophageal cancer	0.00126	0.00152	CcSEcCtD
Valganciclovir—Hepatitis—Methotrexate—esophageal cancer	0.00125	0.00151	CcSEcCtD
Valganciclovir—Haemorrhage—Methotrexate—esophageal cancer	0.00125	0.00151	CcSEcCtD
Valganciclovir—Arthralgia—Capecitabine—esophageal cancer	0.00124	0.0015	CcSEcCtD
Valganciclovir—Pharyngitis—Methotrexate—esophageal cancer	0.00124	0.0015	CcSEcCtD
Valganciclovir—Anxiety—Capecitabine—esophageal cancer	0.00124	0.0015	CcSEcCtD
Valganciclovir—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00124	0.00149	CcSEcCtD
Valganciclovir—Urinary tract disorder—Methotrexate—esophageal cancer	0.00123	0.00149	CcSEcCtD
Valganciclovir—Discomfort—Capecitabine—esophageal cancer	0.00123	0.00149	CcSEcCtD
Valganciclovir—Urethral disorder—Methotrexate—esophageal cancer	0.00123	0.00148	CcSEcCtD
Valganciclovir—Dry mouth—Capecitabine—esophageal cancer	0.00122	0.00147	CcSEcCtD
Valganciclovir—Visual impairment—Methotrexate—esophageal cancer	0.0012	0.00146	CcSEcCtD
Valganciclovir—Confusional state—Capecitabine—esophageal cancer	0.0012	0.00145	CcSEcCtD
Valganciclovir—Oedema—Capecitabine—esophageal cancer	0.00119	0.00144	CcSEcCtD
Valganciclovir—Hypersensitivity—Cisplatin—esophageal cancer	0.00119	0.00144	CcSEcCtD
Valganciclovir—Infection—Capecitabine—esophageal cancer	0.00119	0.00143	CcSEcCtD
Valganciclovir—Nervous system disorder—Capecitabine—esophageal cancer	0.00117	0.00141	CcSEcCtD
Valganciclovir—Eye disorder—Methotrexate—esophageal cancer	0.00117	0.00141	CcSEcCtD
Valganciclovir—Thrombocytopenia—Capecitabine—esophageal cancer	0.00117	0.00141	CcSEcCtD
Valganciclovir—Tinnitus—Methotrexate—esophageal cancer	0.00117	0.00141	CcSEcCtD
Valganciclovir—Tachycardia—Capecitabine—esophageal cancer	0.00116	0.00141	CcSEcCtD
Valganciclovir—Asthenia—Cisplatin—esophageal cancer	0.00116	0.0014	CcSEcCtD
Valganciclovir—Cardiac disorder—Methotrexate—esophageal cancer	0.00116	0.0014	CcSEcCtD
Valganciclovir—Skin disorder—Capecitabine—esophageal cancer	0.00116	0.0014	CcSEcCtD
Valganciclovir—Hyperhidrosis—Capecitabine—esophageal cancer	0.00115	0.00139	CcSEcCtD
Valganciclovir—Anorexia—Capecitabine—esophageal cancer	0.00114	0.00137	CcSEcCtD
Valganciclovir—SLC6A14—NRF2 pathway—TGFBR2—esophageal cancer	0.00114	0.0188	CbGpPWpGaD
Valganciclovir—Angiopathy—Methotrexate—esophageal cancer	0.00113	0.00137	CcSEcCtD
Valganciclovir—Immune system disorder—Methotrexate—esophageal cancer	0.00113	0.00136	CcSEcCtD
Valganciclovir—Mediastinal disorder—Methotrexate—esophageal cancer	0.00113	0.00136	CcSEcCtD
Valganciclovir—Chills—Methotrexate—esophageal cancer	0.00112	0.00136	CcSEcCtD
Valganciclovir—SLC6A14—NRF2 pathway—HMOX1—esophageal cancer	0.00112	0.0185	CbGpPWpGaD
Valganciclovir—Hypotension—Capecitabine—esophageal cancer	0.00111	0.00135	CcSEcCtD
Valganciclovir—Diarrhoea—Cisplatin—esophageal cancer	0.00111	0.00134	CcSEcCtD
Valganciclovir—Alopecia—Methotrexate—esophageal cancer	0.0011	0.00134	CcSEcCtD
Valganciclovir—Mental disorder—Methotrexate—esophageal cancer	0.0011	0.00132	CcSEcCtD
Valganciclovir—Malnutrition—Methotrexate—esophageal cancer	0.00109	0.00132	CcSEcCtD
Valganciclovir—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00109	0.00131	CcSEcCtD
Valganciclovir—Insomnia—Capecitabine—esophageal cancer	0.00108	0.0013	CcSEcCtD
Valganciclovir—Paraesthesia—Capecitabine—esophageal cancer	0.00107	0.00129	CcSEcCtD
Valganciclovir—Dysgeusia—Methotrexate—esophageal cancer	0.00107	0.00129	CcSEcCtD
Valganciclovir—Dyspnoea—Capecitabine—esophageal cancer	0.00106	0.00129	CcSEcCtD
Valganciclovir—Back pain—Methotrexate—esophageal cancer	0.00105	0.00127	CcSEcCtD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00105	0.0174	CbGpPWpGaD
Valganciclovir—Dyspepsia—Capecitabine—esophageal cancer	0.00105	0.00127	CcSEcCtD
Valganciclovir—Decreased appetite—Capecitabine—esophageal cancer	0.00104	0.00125	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00103	0.00124	CcSEcCtD
Valganciclovir—Vomiting—Cisplatin—esophageal cancer	0.00103	0.00124	CcSEcCtD
Valganciclovir—Fatigue—Capecitabine—esophageal cancer	0.00103	0.00124	CcSEcCtD
Valganciclovir—Vision blurred—Methotrexate—esophageal cancer	0.00103	0.00124	CcSEcCtD
Valganciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	0.00102	0.0169	CbGpPWpGaD
Valganciclovir—Constipation—Capecitabine—esophageal cancer	0.00102	0.00123	CcSEcCtD
Valganciclovir—Pain—Capecitabine—esophageal cancer	0.00102	0.00123	CcSEcCtD
Valganciclovir—Dermatitis—Cisplatin—esophageal cancer	0.00102	0.00123	CcSEcCtD
Valganciclovir—Ill-defined disorder—Methotrexate—esophageal cancer	0.00101	0.00122	CcSEcCtD
Valganciclovir—Anaemia—Methotrexate—esophageal cancer	0.00101	0.00122	CcSEcCtD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000988	0.0163	CbGpPWpGaD
Valganciclovir—Feeling abnormal—Capecitabine—esophageal cancer	0.000983	0.00119	CcSEcCtD
Valganciclovir—Malaise—Methotrexate—esophageal cancer	0.000981	0.00119	CcSEcCtD
Valganciclovir—Vertigo—Methotrexate—esophageal cancer	0.000978	0.00118	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000976	0.00118	CcSEcCtD
Valganciclovir—Leukopenia—Methotrexate—esophageal cancer	0.000974	0.00118	CcSEcCtD
Valganciclovir—Nausea—Cisplatin—esophageal cancer	0.000961	0.00116	CcSEcCtD
Valganciclovir—Cough—Methotrexate—esophageal cancer	0.00095	0.00115	CcSEcCtD
Valganciclovir—Urticaria—Capecitabine—esophageal cancer	0.000948	0.00115	CcSEcCtD
Valganciclovir—Body temperature increased—Capecitabine—esophageal cancer	0.000943	0.00114	CcSEcCtD
Valganciclovir—Abdominal pain—Capecitabine—esophageal cancer	0.000943	0.00114	CcSEcCtD
Valganciclovir—Convulsion—Methotrexate—esophageal cancer	0.000943	0.00114	CcSEcCtD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000937	0.0155	CbGpPWpGaD
Valganciclovir—Arthralgia—Methotrexate—esophageal cancer	0.000926	0.00112	CcSEcCtD
Valganciclovir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00092	0.00111	CcSEcCtD
Valganciclovir—Discomfort—Methotrexate—esophageal cancer	0.000915	0.00111	CcSEcCtD
Valganciclovir—Confusional state—Methotrexate—esophageal cancer	0.000896	0.00108	CcSEcCtD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000894	0.0148	CbGpPWpGaD
Valganciclovir—Anaphylactic shock—Methotrexate—esophageal cancer	0.000888	0.00107	CcSEcCtD
Valganciclovir—Infection—Methotrexate—esophageal cancer	0.000882	0.00107	CcSEcCtD
Valganciclovir—Hypersensitivity—Capecitabine—esophageal cancer	0.000879	0.00106	CcSEcCtD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.000872	0.0144	CbGpPWpGaD
Valganciclovir—Nervous system disorder—Methotrexate—esophageal cancer	0.000871	0.00105	CcSEcCtD
Valganciclovir—Thrombocytopenia—Methotrexate—esophageal cancer	0.00087	0.00105	CcSEcCtD
Valganciclovir—Skin disorder—Methotrexate—esophageal cancer	0.000863	0.00104	CcSEcCtD
Valganciclovir—Hyperhidrosis—Methotrexate—esophageal cancer	0.000859	0.00104	CcSEcCtD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000857	0.0141	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000857	0.0141	CbGpPWpGaD
Valganciclovir—Asthenia—Capecitabine—esophageal cancer	0.000856	0.00103	CcSEcCtD
Valganciclovir—Anorexia—Methotrexate—esophageal cancer	0.000847	0.00102	CcSEcCtD
Valganciclovir—Pruritus—Capecitabine—esophageal cancer	0.000844	0.00102	CcSEcCtD
Valganciclovir—Hypotension—Methotrexate—esophageal cancer	0.00083	0.001	CcSEcCtD
Valganciclovir—Diarrhoea—Capecitabine—esophageal cancer	0.000816	0.000987	CcSEcCtD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.000809	0.0134	CbGpPWpGaD
Valganciclovir—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000809	0.000978	CcSEcCtD
Valganciclovir—Insomnia—Methotrexate—esophageal cancer	0.000803	0.000971	CcSEcCtD
Valganciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.000798	0.0132	CbGpPWpGaD
Valganciclovir—Paraesthesia—Methotrexate—esophageal cancer	0.000797	0.000964	CcSEcCtD
Valganciclovir—Dyspnoea—Methotrexate—esophageal cancer	0.000792	0.000957	CcSEcCtD
Valganciclovir—Somnolence—Methotrexate—esophageal cancer	0.00079	0.000954	CcSEcCtD
Valganciclovir—Dizziness—Capecitabine—esophageal cancer	0.000789	0.000954	CcSEcCtD
Valganciclovir—Dyspepsia—Methotrexate—esophageal cancer	0.000782	0.000945	CcSEcCtD
Valganciclovir—Decreased appetite—Methotrexate—esophageal cancer	0.000772	0.000933	CcSEcCtD
Valganciclovir—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000767	0.000927	CcSEcCtD
Valganciclovir—Fatigue—Methotrexate—esophageal cancer	0.000766	0.000926	CcSEcCtD
Valganciclovir—Pain—Methotrexate—esophageal cancer	0.000759	0.000918	CcSEcCtD
Valganciclovir—Vomiting—Capecitabine—esophageal cancer	0.000759	0.000917	CcSEcCtD
Valganciclovir—Dermatitis—Capecitabine—esophageal cancer	0.000752	0.000908	CcSEcCtD
Valganciclovir—Headache—Capecitabine—esophageal cancer	0.000747	0.000903	CcSEcCtD
Valganciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.00074	0.0122	CbGpPWpGaD
Valganciclovir—Feeling abnormal—Methotrexate—esophageal cancer	0.000732	0.000885	CcSEcCtD
Valganciclovir—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000726	0.000878	CcSEcCtD
Valganciclovir—Nausea—Capecitabine—esophageal cancer	0.000709	0.000857	CcSEcCtD
Valganciclovir—Urticaria—Methotrexate—esophageal cancer	0.000706	0.000853	CcSEcCtD
Valganciclovir—Abdominal pain—Methotrexate—esophageal cancer	0.000702	0.000849	CcSEcCtD
Valganciclovir—Body temperature increased—Methotrexate—esophageal cancer	0.000702	0.000849	CcSEcCtD
Valganciclovir—Hypersensitivity—Methotrexate—esophageal cancer	0.000654	0.000791	CcSEcCtD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.00065	0.0107	CbGpPWpGaD
Valganciclovir—Asthenia—Methotrexate—esophageal cancer	0.000637	0.00077	CcSEcCtD
Valganciclovir—Pruritus—Methotrexate—esophageal cancer	0.000628	0.00076	CcSEcCtD
Valganciclovir—Diarrhoea—Methotrexate—esophageal cancer	0.000608	0.000735	CcSEcCtD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000589	0.00973	CbGpPWpGaD
Valganciclovir—Dizziness—Methotrexate—esophageal cancer	0.000587	0.00071	CcSEcCtD
Valganciclovir—Vomiting—Methotrexate—esophageal cancer	0.000565	0.000683	CcSEcCtD
Valganciclovir—Dermatitis—Methotrexate—esophageal cancer	0.000559	0.000676	CcSEcCtD
Valganciclovir—Headache—Methotrexate—esophageal cancer	0.000556	0.000673	CcSEcCtD
Valganciclovir—Nausea—Methotrexate—esophageal cancer	0.000528	0.000638	CcSEcCtD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000497	0.00821	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000468	0.00772	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000461	0.00762	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000443	0.00731	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000434	0.00716	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000423	0.00698	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000411	0.00679	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000405	0.00669	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000405	0.00669	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000392	0.00648	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000376	0.00621	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000376	0.00621	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000359	0.00593	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000345	0.00569	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000307	0.00507	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000285	0.00471	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000279	0.0046	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000259	0.00427	CbGpPWpGaD
Valganciclovir—SLC6A14—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.00023	0.0038	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.00017	0.0028	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000163	0.00269	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000158	0.0026	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000151	0.0025	CbGpPWpGaD
Valganciclovir—SLC15A2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000109	0.0018	CbGpPWpGaD
Valganciclovir—SLC15A1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000101	0.00167	CbGpPWpGaD
